Skip to main content
Close

Vancouver Centre



If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

Tumour group / siteTrial titleDate opened
BREAST
A phase IIIb, single-arm, open-label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA1/2 mutations
BCCA CODE: BRTLUCY
May 2018

A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For HER2 Negative Breast Cancer: The ABC Trial
BCCA CODE: BRMAC21 
May 2018

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER
BCCA CODE: BRTIPATUNI
May 2018

A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, horone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
BCCA CODE: BRTBYLIEVE
March 2018

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
BCCA CODE: BRMA37
September 2017

A study evaluating the pregnancy outcomes and safety of interupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (positive)
BCCA CODE: BRMAC18

July 2017

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
BCCA CODE: BRTCOMPLEE

July 2017

A randomized, multicenter, double-blind, placebo-controlled phase II study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab-placebo in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab and taxane based therapy
BCCA CODE: BRTKATE2

November 2016

Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy
BCCA CODE: BRTYCA09

November 2016

A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
BCCA CODE: BRMA36
February 2016

A phase III, multicenter, randomized, placebo-controlled study of MPDL3280A(Anti-PD-L1 Antibody) in combination with Nab-Pacilitaxel compared with placebo with Nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer
BCCA CODE: BRT29522
January 2016

A phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
BCCA CODE: BRTPENELOP
November 2015

A phase III, double blind, placebo-controlled, randomized study of Taselisib plus Fulvestrant versus placebo plus Fulvestrant in postmenopausal women with estrogen receptor-positive and HER2 negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy
BCCA CODE: BRTPIPER
July 2015
 A phase II clinical trial to evaluate 18F-Fluorestradiol positron emission tomography / computerized tomography (PET/CT) guided fulvestrant therapy for patients with rosarian or metastatic breast cancer
BCCA CODE: BRTFULCT
November 2010
CENTRAL NERVOUS
SYSTEM (CNS)
A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma (CheckMate 548: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 548)
BCCA CODE: CNT209548
January 2017
GASTROINTESTINAL (GI)
A PHASE III, RANDOMISED, INTERNATIONAL TRIAL COMPARING mFOLFIRINOX TRIPLET CHEMOTHERAPY TO mFOLFOX FOR HIGH RISK STAGE III COLON CANCER IN ADJUVANT SETTING (IROCAS STUDY)
BCCA CODE: GICO27
April 2018

COMPHREHENSIVE GENOMIC PROFILING OF COLORECTAL CANCER PATIENTS WITH ISOLATED LIVER METASTASES TO UNDERSTAND RESPONSE & RESISTANCE TO CANCER THERPAY 
BCCA CODE: GICOMPARIS
April 2018

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma subtypes by comprehensive Genomic Analysis
BCCA CODE: GITPANGEN
February 2017

A phase II randomized study of durvalumab and tremelimumab and best supportive care vs. best supportive care alone in patients with advanced colorectal adenocarcinoma refractory to standard therapies
BCCA CODE: GICO26
January 2017

A randomized phase II trial of gemcitabine and nab-paclitaxel vs gencitabline, nab-paclitaxel and durvalumab and tremelimumab as 1st line therapy in metastatic pancreatic adenocarcinoma
BCCA CODE: GIPA7
October 2016

A randomized multicenter double blind phase III study of nivolumab or placebo in subjects with resected lower esophageal or gastroesophageal junction cancer
BCCA CODE: GIT209577

September 2016


A phase II/III of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.
BCCA CODE: GICRC7
August 2013
 
A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge)
BCCA CODE: GICO21
July 2009

GENITOURINARY (GU) - BLADDER
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (GUTBISCAY)
BCCA CODE: GUTBISCAY
October 2017

A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high risk muscle-invasive bladder cancer after cystectomy
BCCA CODE: GUT29636
March 2016
 

A phase I study of safety and pharmacokinetics of escalating doses of AGS15E given as monotherapy in subjects with metastatic urothelial cancer
BCCA CODE: GUTAGS15E

December 2013

GENITOURINARY (GU) - KidneyA multi-center, open label, randomized phase II study of AGS-16C3F vs axitinib in metastatic renal cell carcinoma
BCCA CODE: GUT16C3F
April 2016
A phase II, multi-centre study, of stereotactic radiotherapy for oligo-progression in metastatic renal cell cancer patients receiving 1st line sunitinib therapy
BCCA CODE: GUTSUNI
December 2015
GENITOURINARY (GU) - TestisGenetic susceptibility and biomarkers of platinum-related toxicities (The Platinum Study).
BCCA CODE: GUTPLATINU (on HOLD as of January 23, 2015)
January 2015
GENITOURINARY
(GU) - Prostate
An International Registry for Men with Advanced Prostate Cancer
BCCA CODE: IRONMAN
April 2018

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
BCCA CODE: GUTCR2001
December 2017

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
BCCA CODE: GUT39303
December 2017

A Phase III, Randomized, Open Label, Randomized Study To Assess the Efficacy and Safety of Olaparib (LynparzaTM) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations
BCCA CODE: GUTPROFOUN
November 2017

A Safety and Pharmacokinetics Study of Niraparib plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate plus Prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer

BCCA CODE: GUTBEDIVER

June 2017

A phase II study of durvalumab (MEDI4736) with or without tremelimumab in patients with castration resistant prostate cancer
BCCA CODE: GUIND232
January 2017
A phase I/II open-label study to assess the safety, pharmcokinetics, and anti-tumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer
BCCA CODE: GUTCS0001
(on HOLD as of January 9, 2015)
December 2015
 
A randomized phase II study of sequencing abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
BCCA CODE: GUTABIENZA
September 2014
GYNECOLOGY
​Phase I (Safety Assessment) of Durvalumab (MEDI4736) with Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma 
BCCA CODE: GOTABSRT
​May 2018

A Retrospective/
Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours

BCCA CODE: 
GOTOZM061

August 2017

A phase 3 randomized, double-blind, placebo-controlled multicentre study of Niraparib maintenance treatment in patients with HRD-positive advanced ovarian cancer following response to front-line platinum-based chemotherapy
BCCA CODE: GOTPRIMA
February 2017
HEAD & NECKA two-arm, open-label, randomized phase II study of Pembrolizumab (MK3475) monotherapy versus standard chemotherapy in platinum pre-treated, recurrent or metastatic nasopharyngeal cancer
BCCA CODE: HNT3475122
June 2016
LUNG
A Phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients withtreatment-naïve advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy
BCCA CODE: LUT29872
December 2017

Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum-based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer 
BCCA CODE: LUBR34
October 2017

A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
BCCA CODE: LUBR31
July 2015

A randomized phase II trial of selumetinib in patients receiving standard pemetrexed and cisplatin chemotherapy for the treatment of advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer
BCCA CODE: LUIND219
(on HOLD as of June 10, 2015)
June 2015
LYMPHOMA
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies
BCCA CODE: LYT209647
May 2018

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
BCCA CODE: LYT209647

July 2017

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic malignancies
BCCA CODE: LYTTT1621

May 2017

An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell non-hodgkin's lymphoma and chronic lymphocytic leukemia (CLL)
BCCA CODE: LYT29781
February 2016

A phase I/II study to evaluate the safety and preliminary efficacy of nivolumab in combination with brentuximab vedotin in subjects with relapsed refractory non-hodgkin lymphomas with CD30 expression CheckMate 436: CHECKpoint pathway and nivolumab clinical trial evaluation
BCCA CODE: LYT209436
December 2015

A multi-staged randomized phase II study of novel combination therapy in the treatment of relapsed and refractory aggressive B-cell lymphoma
BCCA CODE: LYLY17
September
2015

A phase IB/II, open-label study evaluting the safety and pharmacokenetics of GDC-0199 (ABT-199) in combination with rituximab(R) or obinutuzumab(G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B-cell non-hodgkin's lymphoma (NHL) and DLBCL
BCCA CODE: LYT27878
February 2015
PHASE 1
A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
April 2018

CANADIAN PROFILING AND TARGETED AGENT UTILIZATION TRIAL (CAPTUR) A PHASE II BASKET TRIAL
BCCA CODE: P1PM1
March 2018

A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
BCCA CODE: P1T1143 
March 2018

A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
BCCA CODE: P1PJC021
January 2018

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
BCCA CODE: P1TGARNET
September 2017

A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
BCCA CODE: P1TLEETMT 
September 2017

A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in patients with Advanced Solid TumorsSeptember 2017

A Phase I trial of MLN0128 (Tak-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor.

BCCA CODE: P1PJC020

September 2017


A Phase II Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
BCCA CODE: P1PJC022

August 2017


An open-label, dose escalation, safety, and pharmacokinetic study of CFI-402257 administered orally to patients with advanced solid tumours
BCCA CODE: P1T402257
May 2017

A phase II study of durvalumab (MEDI4736) and tremelimumab in patients with advanced rare tumours
BCCA CODE: MOIND228
April 2017

A phase I/Ib, open-label, multi-center, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with selected incurable cancers
BCCA CODE: P1TCPI444
February 2017

A phase I/II study of CX5461
BCCA CODE: P1IND231
September 2016

A phase I/IIa study of BMS-986205 in combination with nivolumab (BMS-986558, anti PD-1 Monoclonal Antibody) in advanced malignant tumors
BCCA CODE: P1T986205
April 2016

A phase I trial of MK-3475 Plus Ziv-Aflibercept in patients with advanced solid tumours
BCCA CODE: P1PJC016
August 2015

A phase I/II study of MG1 MARABA/MAGE-A3 (MG1MA3), with and without adenovirus vaccine, with transgenic MAGE-A3 insertion (AdMA3) in patients with incurable advanced metastatic MAGE-A3 expressing solid tumours
BCCA CODE: P1IND214
July 2015
 A phase I trial of single agent trametinib (GSK1120212) in advanced cancer patients with dysfunction
BCCA CODE: P1PJC015
June 2014
 A phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in patients with advanced solid malignancies
BCCA CODE: P1TGIVEN
June 2014
SARCOMA
 
SKIN - MELANOMA
A phase III randomized, double-blind, placebo-controlled study comparing the combination of PDR001, daBRAFenib and trametinib versus placebo, daBRAFenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
BCCA CODE: SMTCOMBII 
May 2018

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP)
BCCA CODE: SMME13
October 2016
SYMPTOM MANAGEMENT/
SUPPORTIVE CARE

A randomized, double-blind, placebo controlled crossover trial of the use of Subcutaneous Lidocaine Infusion (SCLI) for chronic cancer-related pain
BCCA CODE: LIDOCAINE
 January 2012

Sennosides PEG study
A randomized, double-blind, double-dummy, 2 treament, 2 period, cross-over comparison of Sennosides and Polyethylene Glycol for constipation in outpatients with cancer
BCCA CODE: SCTPEGSEN
April 2010
MULTIPLE
SITES
Utilization of genomic information to augment chemotherapy decision-making for people with incurable malignancies
BCCA CODE: no BCCA code available
July 2012















SOURCE: Vancouver Centre ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority